Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion: Preliminary results

Hepatology Research

Volumn 39, Issue 2, 2009, Pages 117-125

  Kasai, Kazuhiro ^a   Kuroda, Hidekatsu ^a   Ushio, Akira ^a   Sawara, Kei ^a   Takikawa, Yasuhiro ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Hepatocellular carcinoma; PEG IFN 2b; Portalvenous invasion

Indexed keywords

FLUOROURACIL; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTIBODY TITER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS C; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 59149099756     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00414.x     Document Type: Article

References (44)

1. Shinagawa T, Ohto M, Kimura K et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography: A study in 51 patients. Gastroenterology 1984; 2: S21-26.
2. Takayasu K, Shima Y, Muramatsu Y et al. Angiography of small hepatocellular carcinomas: Analysis of 105 resected tumors. Am J Roentgenol 1986; 147: 525-9.
3. Matsui O, Takashima T, Kadoya M et al. Dynamic computed tomography during arterial portography; the most sensitive examination for hepatocellular carcinomas. J Comput Assist Tomogr 1985; 9: 19-24.
4. Ohtomo K, Furui S, Kokubo T et al. Transcatheter arterial embolization (TAE) in treatment for hepatoma-analysis of three-year survivors. Radiat Med 1985; 3: 176-80.
5. Shiina S, Tagawa K, Unuma T et al. Percutaneous ethanol injection therapy for treatment of hepatocellular carcinoma. Am J Roentgenol 1990; 154: 947-51.
6. Sato M, Watanabe Y, Ueda S et al. Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology 1996; 110: 1507-14.
7. Shiina S, Teratani T, Obi S et al. Nonsurgical treatment of hepatocellular carcinoma: From percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62 (Suppl 1): 64-8. Review.
8. Stehlin JS Jr, de Ipolyi PD, Greeff PJ et al. Treatment of cancer of the liver: Twenty years' experience with infusion and resection in 414 patients. Ann Surg 1998; 208: 23-35.
9. Doci R, Bignami P, Bozzetti F et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988; 61: 1983-7.
10. Olweny CH, Toya T, Katongole-Mobidof F et al. Treatment of hepatocellular carcinoma with adriamycin. Cancer 1975; 36: 1250-7.
11. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
12. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.
13. Paul G, Jane WSF, Regine R et al. Pegylated interferon-a2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556-67.
14. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
15. Irie T. Intraarterial chemotherapy of liver metastasis: Implantation of microcatheter-port system with use of modified fixed catheter tip technique. J Vasc Interv Radiol 2001; 12: 1215-18.
16. Strader DB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-69.
17. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
18. NCI Common Toxicity Criteria. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). [Cited 9 August 2006.] Available from URL: http://ctep.cancer.gov/reporting/ctc.html
19. Fujii T, Takayasu K, Muramatsu Y et al. Hepatocellular carcinoma with portal tumor thrombus: Analysis of factors determining prognosis. Jpn J Clin Oncol 1993; 23: 105-9.
20. Chen SC, Hsieh MY, Chuaug WL et al. Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol 1994; 9: 1-6.
21. Tanaka A, Morimoto T, Yamaoka Y et al. Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology 1996; 43: 637-43.
22. Ando E, Yamashita F, Tanaka M et al. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-6.
23. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
24. Schwartz EL, Hoffman M, O'Connor CJ et al. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 1992; 182: 1232-9.
25. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990; 50: 3473-86.
26. Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989; 163: 867-74.
27. Kondo M, Nagano H, Wada H et al. Combination of IFN-a and 5-fluorouracil induces apoptosis through IFN-a/β receptor in human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 1277-86.
28. Sabaawy HE, Farley T, Ahmed T et al. Synergistic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol 1999; 101: 82-8.
29. Yano H, Iemura A, Haramaki M et al. Interferon alpha receptor expression and growth inhibition by interferon alpha in human liver cell lines. Hepatology 1999; 29: 1708-17.
30. Sangfelt O, Erickson S, Gastro J et al. Molecular mechanisms underlying interferon alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 CDK-complexes and activation of pocket proteins. Oncogene 1999; 18: 2798-810.
31. Kimchi A. Cytokine triggered molecular pathways that control cell cycle arrest. J Cell Biochem 1992; 50: 1-9.
32. Guadagni F, Schlom J, Johnston WW et al. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 1989; 81: 502-12.
33. Ortaldo JR, Mantovani A, Hobbs D et al. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer 1983; 31: 285-9.
34. Lindahl P, Leary R, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972; 69: 721-5.
35. Uno K, Shimizu S, Ido M et al. Direct and indirect effects of interferon on in vivo murine tumor cell growth. Cancer Res 1985; 45: 1320-7.
36. Yano H, Yanai Y, Momosaki S et al. Growth inhibitory effects of pegylated IFNa-2b on human liver cancer cells in vitro and in vivo. Liver Int 2006; 26: 964-75.
37. Kurokohchi K, Takaguchi K, Kita K et al. Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon α. World J Gastrol 2005; 11: 5401-3.
38. Silva M, Poo J, Wagner F et al. A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45: 204-13.
39. Obi S, Imamura J, Kanda M et al. Combination therapy of intra arterial 5FU and systemic interferon-a for advanced hepatocellular carcinoma with portal venous invasion. Gastroenterology (Tokyo) 2006; 43: 260-8. (In Japanese.)
40. Foster GR. ReviewCarticle: Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825-30.
41. Drewinko B, Yang L-Y. Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep 1985; 69: 1391-8.
42. Guchelaar HJ, Vermes I, Koopmans RP et al. Apoptosis-and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: A quantitative pharmacodynamic model. Cancer Chemother Pharmacol 1998; 42: 77-83.
43. Ueshima K, Tatsumi C, Sakaguchi Y et al. Breakthrough of the hepatic arterial infusion chemotherapy of hepatocellular carcinoma. Gastroenterology (Tokyo) 2006; 43: 253-9. (In Japanese.)
44. Stephan FS, Markus S, Christoph PB et al. Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells. Antimicrob Agents Chemother 2003; 47: 1912-21.